|   Phase II-IV   |   No comment

Breakthrough Therapy Designation from U.S. Food and Drug Administration for Two Drugs for Patients with Major Depressive Disorder with Imminent Risk for Suicide

Major depressive disorder (MDD) affects approximately 16 million people in the U.S. and 121 million people worldwide. As per the report on global burden of disease, the estimated point prevalence of unipolar depressive episodes is 1.9% and 3.2% among men and women, and the one-year...

Read More
01 September
1